Research & Innovation

News & Research:

Training the Next Generation of Cancer Scholars

Open Clinical Trials:

Bladder Cancer (common type of bladder cancer is called Urothelial Carcinoma)
Study Title: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible 
Primary Investigator: Dr. Alexandro Recio Boiles
 
Study Title: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Primary Investigator: Dr. Alexandro Recio Boiles
 
Study Title: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Primary Investigator: Dr. Alexandro Recio Boiles
 
Kidney Cancer (also called Renal Cell Carcinoma)
Study Title: Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)
Primary Investigator: Dr. Benjamin Lee
 
Study Title: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab in Combination with Cabozantinib in Patients with Renal Cell Carcinoma who Experienced Disease Progression During or After Check Point Inhibitor Treatment (Contact-03)
Primary Investigator:  Dr. Edward P. Gelmann
 
Kidney Stones

Study Title: Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
Primary Investigator: Dr. David T. Tzou

Prostate Cancer
Study Title: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Primary Investigator: Dr. Juan Chipollini
 
Study Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab in Combination with Docetaxel versus Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7DX)
Primary Investigator: Dr. Alexandro Recio Boiles
 

Study Title: First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer
Primary Investigator: Dr. Edward P. Gelmann

For more information or questions, contact Dr. Juan Chipollini at jchipollini@surgery.arizona.edu